keyword
MENU ▼
Read by QxMD icon Read
search

Etanercept

keyword
https://www.readbyqxmd.com/read/29452300/therapeutic-strategy-for-rheumatoid-arthritis-patients-who-have-achieved-remission
#1
Bruno Fautrel
Once remission or low disease activity (LDA) is attained in established rheumatoid arthritis (RA) patients, attempting disease-modifying anti-rheumatic drug (DMARD) tapering appears to be a viable option to avoid patient overtreatment. Potential benefits include reduction in the treatment burden and the risk of adverse events, although the latter has not been demonstrated convincingly.The feasibility of DMARD discontinuation has been tested in numerous studies or trials. All have revealed a high risk of relapse, ranging from 56% to 87% at one year...
February 13, 2018: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/29452218/tnf%C3%AE-disrupts-blood-brain-barrier-integrity-to-maintain-prolonged-depressive-like-behavior-in-mice
#2
Yuyan Cheng, Sachi Desse, Ana Martinez, Ryan J Worthen, Richard S Jope, Eleonore Beurel
Recovery from major depressive disorder is difficult, particularly in patients who are refractory to antidepressant treatments. To examine factors that regulate recovery, we developed a prolonged learned helplessness depression model in mice. After the induction of learned helplessness, mice were separated into groups that recovered or did not recover within 4 weeks. Comparisons were made between groups in hippocampal proteins, inflammatory cytokines, and blood brain barrier (BBB) permeability. Compared with mice that recovered and control mice, non-recovered mice displaying prolonged learned helplessness had greater hippocampal activation of glycogen synthase kinase-3 (GSK3), higher levels of tumor necrosis factor-α (TNFα), interleukin-17A, and interleukin-23, increased permeability of the blood brain barrier (BBB), and lower levels of the BBB tight junction proteins occludin, ZO1, and claudin-5...
February 13, 2018: Brain, Behavior, and Immunity
https://www.readbyqxmd.com/read/29448850/treatment-changes-in-patients-with-psoriasis-on-etanercept-or-adalimumab-a-retrospective-chart-review
#3
Erica B Lee, Mina Amin, Alexander Egeberg, Jashin J Wu
PURPOSE: To determine the frequency of and reasons for treatment changes in patients with psoriasis. MATERIALS AND METHODS: A retrospective chart review of 140 patients with psoriasis treated with adalimumab or etanercept seen at Kaiser Permanente Los Angeles Medical Center between September 20, 2004 and September 8, 2017 was conducted. The first treatment change and reason for that change was documented. RESULTS: Of 140 patients, 103 patients had treatment changes, most commonly due to inefficacy, however complicating events and changes due to patient preference were also seen...
February 15, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29447638/pediatric-pustular-psoriasis-responsive-to-cyclosporine-bridged-to-etanercept-a-treatment-approach
#4
Corey Georgesen, Horatio Wildman, Xuan Wang, Cynthia Magro
Pustular psoriasis occurs rarely in children but can present with acute toxicity requiring inpatient admission. For the best approach, medical providers should have an evidence based and systematic treatment algorithm in their armamentarium. Toillustrate this point, we describe a 13-year-old girl who was admitted with generalized pustular psoriasis and who responded dramatically to "wet wrap" therapy and cyclosporine bridged to etanercept. Using this case example, we highlight the three most important considerations in any patient with new onset pustularpsoriasis: avoidance of disease complications, acute "rescue" therapy, and maintenance therapy...
November 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/29446857/infectious-risk-of-biological-drugs-versus-traditional-systemic-treatments-in-moderate-to-severe-psoriasis-a-cohort-analysis-in-the-french-insurance-database
#5
Sylvain Couderc, Maryse Lapeyre-Mestre, Robert Bourrel, Paul Carle, Jean-Louis Montastruc, Agnès Sommet
The aim of this study was to compare the infectious risk between a group of psoriasis patients treated by Biological Drugs (BD) and a group treated by Traditional Systemic Treatments (TST). We built a retrospective observational cohort study from the French health insurance database in the Midi-Pyrénées area (2.9 million inhabitants, South West of France) using data from 01/01/2010 to 12/31/2013. We compared the infectious risk between 'exposed' patients treated with BD (adalimumab, etanercept, infliximab or ustekinumab) and 'unexposed' patients treated by TST (phototherapy, acitretin, methotrexate or cyclosporine)...
February 15, 2018: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/29445863/use-of-biological-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-in-austria-from-2008-to-2011-a-retrospective-analysis-of-72-of-the-population
#6
Tanja A Stamm, Berthold Reichardt, Jochen Zwerina, Valentin Ritschl, Valerie Nell-Duxneuner
BACKGROUND: Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease. On a national level in Austria, there are currently no data available on how often and which biological disease modifying antirheumatic drugs (bDMARDs) are prescribed in patients with RA. The aim of the present study was to explore prescription patterns of bDMARDs in RA in Austria with a focus on drug survival. METHODS: A retrospective data analysis of bDMARD courses of individual patients with RA that were extracted from the databases of nine Austrian health insurance funds covering 6...
February 14, 2018: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/29441991/efficacy-and-mechanism-of-action-of-etanercept-in-bone-cancer-pain
#7
Yayong Liao, Meng Xu
Bone cancer pain treatment remains a major clinical challenge, and the mechanism underlying bone cancer pain remains insufficiently understood. The purpose of the current study was to evaluate the efficacy of etanercept, a TNF- inhibitor, against bone cancer pain in an established bone cancer pain model. The mechanical pain threshold value was tested, and the expression of inflammatory factors, NOS, MrgC and NR2B were assessed. The results showed that etanercept decreases the mechanical pain threshold value and inhibits expression of inflammatory factors, NOS, MrgC and NR2B...
April 1, 2017: Die Pharmazie
https://www.readbyqxmd.com/read/29440950/relationship-between-etanercept-and-thyroid-function-in-patients-with-psoriasis-vulgaris
#8
Iulia Ioana Roman, Teodora Mocan, Meda-Sandra Orasan, Elena Mihaela Jianu, Carmen-Angela Sfrangeu, Remus-Ioan Orasan
Background and aim: Psoriasis vulgaris, a chronic inflammatory skin disease, requires a long term medication, in order to avoid relapsing episodes. TNF-alpha, one of the targeted molecule in psoriasis therapy, seems to be also involved in thyroid disorders etiopathogenesis. The aim of this study was to evaluate the relationship between anti TNF-alpha therapy and thyroid parameters: serum level of triiodothyronine (T3), free thyroxine (FT4), thyroid-stimulating hormone (TSH) and antithyroidperoxidase antibody (AbTPO) in psoriasis treated population...
2018: Clujul Medical (1957)
https://www.readbyqxmd.com/read/29438757/comparative-effectiveness-of-targeted-immunomodulators-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-a-systematic-review-and-network-meta-analysis
#9
REVIEW
Anne M Loos, Shanshan Liu, Celia Segel, Daniel A Ollendorf, Steven D Pearson, Jeffrey A Linder
BACKGROUND: The comparative effectiveness of available targeted immunomodulators for moderate-to-severe psoriasis has not been evaluated. OBJECTIVE: To evaluate the comparative effectiveness of targeted immunomodulators for adults with moderate-to-severe plaque psoriasis. METHODS: Systematic literature review of placebo-controlled and head-to-head randomized trials of eight targeted immunomodulators that evaluated clinical benefits or harms...
February 10, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29436715/tnf-%C3%AE-level-affects-etanercept-clearance-tnf-%C3%AE-concentration-as-a-new-correction-factor-of-allometric-scaling-to-predict-individual-etanercept-clearances-in-patients-with-ankylosing-spondylitis
#10
Yuwei Deng, Li Hu, Wei Qiang, Zeneng Cheng, Lei Wang, Xiaoxia Wang
Etanercept (ETN) is a widely used anti- tumor necrosis factor-α (TNF-α) agent, which relieves the symptoms of ankylosing spondylitis (AS) by binding to TNF-α to inhibit its inflammation effects. In this study, the effect of TNF-α level on ETN clearance (CL) was investigated, and the TNF-α concentration was initially set as a correction factor for allometric scaling to improve the predictions of individual ETN CLs. Individual ETN CLs and TNF-α concentrations in healthy volunteers and patients with AS were determined by performing ETN pharmacokinetic studies in the two cohorts...
February 13, 2018: Clinical and Experimental Pharmacology & Physiology
https://www.readbyqxmd.com/read/29430171/correlation-between-hla-haplotypes-and-the-development-of-antidrug-antibodies-in-a-cohort-of-patients-with-rheumatic-diseases
#11
Maurizio Benucci, Arianna Damiani, Francesca Li Gobbi, Francesca Bandinelli, Maria Infantino, Valentina Grossi, Mariangela Manfredi, Guillaume Noguier, Francesca Meacci
Introduction: The aim of this study was to investigate the correlation between human leukocyte antigen (HLA) haplotypes and the development of antidrug antibodies (ADAs) in a cohort of patients with rheumatic diseases. Patients and methods: We evaluated the presence of ADAs in 248 patients with inflammatory rheumatic diseases after 6 months of treatment with anti-TNF drugs: 26 patients were treated with infliximab (IFX; three with rheumatoid arthritis [RA], 13 with ankylosing spondylitis [AS], 10 with psoriatic arthritis [PsA]); 83 treated with adalimumab (ADA; 24 with RA, 36 with AS, 23 with PsA); 88 treated with etanercept (ETA; 35 with RA, 27 with AS, 26 with PsA); 32 treated with certolizumab (CERT; 25 with RA, two with AS, five with PsA); and 19 treated with golimumab (GOL; three with RA, seven with AS, nine with PsA)...
2018: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/29427176/satisfaction-with-subcutaneous-golimumab-and-its-auto-injector-among-rheumatoid-arthritis-patients-with-inadequate-response-to-adalimumab-or-etanercept
#12
Raphael J Dehoratius, Lawrence H Brent, Jeffrey R Curtis, Lorie A Ellis, Kezhen L Tang
BACKGROUND: Patient perceptions of treatment success, including satisfaction/preference, may complement clinical efficacy assessments. OBJECTIVE: Our objective was to evaluate satisfaction with subcutaneous golimumab and its auto-injector in patients with rheumatoid arthritis (RA) and an inadequate adalimumab/etanercept response. METHODS: In the multicenter, assessor-blinded GO-SAVE study, 433 patients with active RA (28-joint Disease Activity Score incorporating erythrocyte sedimentation rate [DAS28-ESR] ≥ 3...
February 9, 2018: Patient
https://www.readbyqxmd.com/read/29424306/biologic-therapy-in-psoriasis-part-i-efficacy-and-safety-of-tumor-necrosis-factor-%C3%AE-inhibitors
#13
A Campanati, E Molinelli, G Ganzetti, V Brisigotti, A Offidani
BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory disorder, with an estimated global prevalence of 2-3%. Psoriasis is associated with an impaired health-related quality of life and a substantial economic burden. Biologics, which target the pathways involved in the pathogenesis of psoriasis, represent an established therapeutic approach for moderate-to-severe plaque psoriasis, with remarkable efficacy and safety profile extensively examined and monitored. METHODS: Biological therapies currently available can be divided into three main categories: the TNFα antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab pegol), the interleukin (IL)-12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab)...
February 9, 2018: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/29421925/pediatric-stevens-johnson-syndrome-toxic-epidermal-necrolysis-halted-by-etanercept
#14
Geneviève M Gavigan, Nordau D Kanigsberg, Michele L Ramien
We report a case of an 11-year-old female with Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) overlap, most likely triggered by sulfamethoxazole-trimethoprim, who was treated with the combination of methylprednisolone, cyclosporine, and etanercept. Her condition stabilized and her skin involvement did not progress after the addition of etanercept. To our knowledge, this is the first report of etanercept for pediatric SJS/TEN.
February 1, 2018: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/29421215/sweeping-of-adsorbed-therapeutic-protein-on-prefillable-syringes-promotes-micron-aggregate-generation
#15
Takahiro Maruno, Hiroki Watanabe, Saki Yoneda, Takayuki Uchihashi, Satoru Adachi, Kunihito Arai, Taichi Sawaguchi, Susumu Uchiyama
This study evaluated how differences in the surface properties of prefillable syringe (PFS) barrels and in-solution sampling methods affect micron aggregates and protein adsorption levels. Three syringe types [glass barrel with silicone oil coating (GLS/so+), glass barrel without silicone oil coating (GLS/so-) and cyclo-olefin polymer (COP) barrel syringes] were tested with three therapeutic proteins (adalimumab, etanercept, and infliximab) using two sampling methods (aspiration or ejection). After quiescent incubation, solutions sampled by aspiration exhibited no significant change in micron aggregate concentration in any syringes, whereas those sample by ejection exhibited increased micron aggregates in both GLS syringe types...
February 5, 2018: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29419448/the-sex-influence-on-response-to-tumor-necrosis-factor-%C3%AE-inhibitors-and-remission-in-axial-spondyloarthritis
#16
Ennio Lubrano, Fabio Massimo Perrotta, Maria Manara, Salvatore D'Angelo, Olga Addimanda, Roberta Ramonda, Leonardo Punzi, Ignazio Olivieri, Carlo Salvarani, Antonio Marchesoni
OBJECTIVE: The aim of this study was to evaluate the influence of sex on response to treatment and disease remission in patients with axial spondyloarthritis (axSpA). METHODS: In this retrospective multicenter study, patients with axSpA, according to the Assessment of Spondyloarthritis international Society (ASAS) criteria for axSpA, and treated with adalimumab, etanercept, golimumab, or infliximab, were studied. We compared clinical characteristics, patient-reported outcomes, disease activity, function, and response to treatment in male and female patients with this disease...
February 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29418106/biosimilars-in-der-dermatologie%C3%A2-theorie-wird-realit%C3%A3-t
#17
REVIEW
Sascha Gerdes, Ulrich Mrowietz, Matthias Augustin, Ralph von Kiedrowski, Alexander Enk, Klaus Strömer, Michael P Schön, Marc A Radtke
Biosimilars sind biologische Medikamente, bei denen es sich um Nachbildungen eines spezifischen Referenzprodukts handelt. Biosimilars der Tumornekrosefaktor-alpha-Inhibitoren Infliximab und Etanercept sind bereits zugelassen und stehen für dermatologische Indikationen zur Verfügung. Die Aufsichtsbehörden verlangen eine eingehende Analyse der physikochemischen und funktionellen Eigenschaften dieser hochkomplexen Moleküle sowie klinische Daten hinsichtlich ihrer gleichwertigen Wirksamkeit und Sicherheit anhand mindestens einer klinischen Studie mit einer sensitiven und homogenen Population...
February 2018: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/29416343/biological-therapy-of-traditional-therapy-resistant-adult-onset-still-s-disease-an-evidence-based-review
#18
REVIEW
Sha Zhou, Jianjun Qiao, Juan Bai, Yinhua Wu, Hong Fang
Background: Biotherapy is becoming increasingly important in the treatment of adult-onset Still's disease (AOSD). The aim of our study was to evaluate the efficacy and safety of biological therapy for AOSD resistant to traditional therapy. Patients and methods: Database of Library of Congress, the PubMed, and Web of Science Core Collection were used to retrieve relevant articles published in English language until March 2017. Only studies published in English language were included, and the additional references quoted in these articles were also checked...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29411222/physicochemical-characterization-glycosylation-pattern-and-biosimilarity-assessment-of-the-fusion-protein-etanercept
#19
Othman Montacir, Houda Montacir, Andreas Springer, Stephan Hinderlich, Fereidoun Mahboudi, Amirhossein Saadati, Maria Kristina Parr
Etanercept is a soluble fusion protein of the tumor necrosis factor receptor (TNFR) extracellular domain, linked to an Fc part of IgG1. It possesses three N- and 13 O-glycosylation sites. Due to its complex structure, an analytical challenge is facing the development and approval of biosimilars. In the current study, physicochemical characterization using state-of-the-art analytics was performed to analyze intact and subunit masses, post-translational modifications (PTMs), higher order structure and potency of Etanercept originator Enbrel® and its biosimilar Altebrel™ (AryoGen Pharmed) in accordance to critical quality attributes of biopharmaceuticals...
February 6, 2018: Protein Journal
https://www.readbyqxmd.com/read/29404710/the-impact-of-inadequate-temperature-storage-conditions-on-aggregate-and-particle-formation-in-drugs-containing-tumor-necrosis-factor-alpha-inhibitors
#20
N D Vlieland, M R Nejadnik, H Gardarsdottir, S Romeijn, A S Sediq, M L Bouvy, A C G Egberts, B J F van den Bemt, W Jiskoot
PURPOSE: To measure aggregate and particle formation in tumor necrosis factor-alpha (TNF-α) inhibitors etanercept, adalimumab and certolizumab pegol product samples after exposure to freezing temperature conditions similar to storage conditions previously observed in patients' homes. METHODS: TNF-α inhibitors in their original primary and secondary packaging were exposed to 32 freeze-thaw cycles (-10°C for 120min/5°C for 60 min) or continuous low storage temperature (-20°C for 96 h) before thawing at 2-8°C...
February 5, 2018: Pharmaceutical Research
keyword
keyword
26126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"